Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmion Corp.

Division of Bristol-Myers Squibb Co.
www.pharmion.com

Latest From Pharmion Corp.

Clovis CEO's Rough Guide To European Launches

Local knowledge on the regulatory and commercial fronts is an absolute must to succeed in Europe, Patrick Mahaffy tells Scrip a couple of months after the firm's PARP inhibitor Rubraca hit the German market.

Launches Europe

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration

Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.

Deals M & A

For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon

A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

BioPharmaceutical United States
See All

Company Information

UsernamePublicRestriction

Register